Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
V
323990
vs
K
KOSPI 200
Over the past 12 months, Vaxcell Bio Therapeutics has underperformed KOSPI 200, delivering a return of -52% compared to KOSPI 200's +106% growth.
Stocks Performance
323990 vs KOSPI 200
Performance Gap
323990 vs KOSPI 200
Performance By Year
323990 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Vaxcell Bio Therapeutics
Glance View
Vaxcell Bio Therapeutics is a South Korean biotech company focused on cell-based medicines. It develops immune-cell and stem-cell therapies meant to treat serious diseases, especially cancers and other hard-to-treat conditions. In simple terms, it tries to turn living cells into medicines that doctors can use in patients. The company makes money by selling or licensing its cell-therapy products and by earning service fees from related research, development, and manufacturing work. Its customers are mainly hospitals, medical researchers, and pharmaceutical partners that need specialized cell-therapy know-how, lab work, or production support. That puts Vaxcell in a part of the industry where the value comes from scientific development, regulatory approval, and controlled cell manufacturing rather than mass-market drug sales. What makes the business different is that its products are not standard pills or chemicals. They are living-cell treatments that must be designed, grown, and handled under strict conditions, so the company’s expertise in cell processing and clinical development is central to its role. If its therapies are successful, Vaxcell can participate both in medicine sales and in partnering with other companies that want to use its platform or manufacturing capabilities.